Human T-cell lymphotropic virus type 1 (HTLV-1) proposed vaccines: a systematic review of preclinical and clinical studies
Abstract Background Numerous vaccination research experiments have been conducted on non-primate hosts to prevent or control HTLV-1 infection. Therefore, reviewing recent advancements for status assessment and strategic planning of future preventative actions to reduce HTLV-1 infection and its conse...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-05-01
|
| Series: | BMC Infectious Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12879-023-08289-7 |
| _version_ | 1827948278568714240 |
|---|---|
| author | Niloofar Seighali Arman Shafiee Mohammad Ali Rafiee Dlnya Aminzade Sayed-Hamidreza Mozhgani |
| author_facet | Niloofar Seighali Arman Shafiee Mohammad Ali Rafiee Dlnya Aminzade Sayed-Hamidreza Mozhgani |
| author_sort | Niloofar Seighali |
| collection | DOAJ |
| description | Abstract Background Numerous vaccination research experiments have been conducted on non-primate hosts to prevent or control HTLV-1 infection. Therefore, reviewing recent advancements for status assessment and strategic planning of future preventative actions to reduce HTLV-1 infection and its consequences would be essential. Methods MEDLINE, Scopus, Web of Science, and Clinicaltrials.gov were searched from each database's inception through March 27, 2022. All original articles focusing on developing an HTLV-1 vaccine candidate were included. Results A total of 47 studies were included. They used a variety of approaches to develop the HTLV-1 vaccine, including DNA-based, dendritic-cell-based, peptide/protein-based, and recombinant vaccinia virus approaches. The majority of the research that was included utilized Tax, Glycoprotein (GP), GAG, POL, REX, and HBZ as their main peptides in order to develop the vaccine. The immunization used in dendritic cell-based investigations, which were more recently published, was accomplished by an activated CD-8 T-cell response. Although there hasn't been much attention lately on this form of the vaccine, the initial attempts to develop an HTLV-1 immunization depended on recombinant vaccinia virus, and the majority of results seem positive and effective for this type of vaccine. Few studies were conducted on humans. Most of the studies were experimental studies using animal models. Adenovirus, Cytomegalovirus (CMV), vaccinia, baculovirus, hepatitis B, measles, and pox were the most commonly used vectors. Conclusions This systematic review reported recent progression in the development of HTLV-1 vaccines to identify candidates with the most promising preventive and therapeutic effects. |
| first_indexed | 2024-04-09T12:51:46Z |
| format | Article |
| id | doaj.art-88fff3820bb340eb9173d8f45e73730a |
| institution | Directory Open Access Journal |
| issn | 1471-2334 |
| language | English |
| last_indexed | 2024-04-09T12:51:46Z |
| publishDate | 2023-05-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Infectious Diseases |
| spelling | doaj.art-88fff3820bb340eb9173d8f45e73730a2023-05-14T11:09:56ZengBMCBMC Infectious Diseases1471-23342023-05-0123114110.1186/s12879-023-08289-7Human T-cell lymphotropic virus type 1 (HTLV-1) proposed vaccines: a systematic review of preclinical and clinical studiesNiloofar Seighali0Arman Shafiee1Mohammad Ali Rafiee2Dlnya Aminzade3Sayed-Hamidreza Mozhgani4Student Research Committee, School of Medicine, Alborz University of Medical SciencesStudent Research Committee, School of Medicine, Alborz University of Medical SciencesSchool of Medicine, Shahid Beheshti University of Medical SciencesSchool of Medicine, Shahid Beheshti University of Medical SciencesDepartment of Microbiology, School of Medicine, Alborz University of Medical SciencesAbstract Background Numerous vaccination research experiments have been conducted on non-primate hosts to prevent or control HTLV-1 infection. Therefore, reviewing recent advancements for status assessment and strategic planning of future preventative actions to reduce HTLV-1 infection and its consequences would be essential. Methods MEDLINE, Scopus, Web of Science, and Clinicaltrials.gov were searched from each database's inception through March 27, 2022. All original articles focusing on developing an HTLV-1 vaccine candidate were included. Results A total of 47 studies were included. They used a variety of approaches to develop the HTLV-1 vaccine, including DNA-based, dendritic-cell-based, peptide/protein-based, and recombinant vaccinia virus approaches. The majority of the research that was included utilized Tax, Glycoprotein (GP), GAG, POL, REX, and HBZ as their main peptides in order to develop the vaccine. The immunization used in dendritic cell-based investigations, which were more recently published, was accomplished by an activated CD-8 T-cell response. Although there hasn't been much attention lately on this form of the vaccine, the initial attempts to develop an HTLV-1 immunization depended on recombinant vaccinia virus, and the majority of results seem positive and effective for this type of vaccine. Few studies were conducted on humans. Most of the studies were experimental studies using animal models. Adenovirus, Cytomegalovirus (CMV), vaccinia, baculovirus, hepatitis B, measles, and pox were the most commonly used vectors. Conclusions This systematic review reported recent progression in the development of HTLV-1 vaccines to identify candidates with the most promising preventive and therapeutic effects.https://doi.org/10.1186/s12879-023-08289-7HTLV-1Vaccine |
| spellingShingle | Niloofar Seighali Arman Shafiee Mohammad Ali Rafiee Dlnya Aminzade Sayed-Hamidreza Mozhgani Human T-cell lymphotropic virus type 1 (HTLV-1) proposed vaccines: a systematic review of preclinical and clinical studies BMC Infectious Diseases HTLV-1 Vaccine |
| title | Human T-cell lymphotropic virus type 1 (HTLV-1) proposed vaccines: a systematic review of preclinical and clinical studies |
| title_full | Human T-cell lymphotropic virus type 1 (HTLV-1) proposed vaccines: a systematic review of preclinical and clinical studies |
| title_fullStr | Human T-cell lymphotropic virus type 1 (HTLV-1) proposed vaccines: a systematic review of preclinical and clinical studies |
| title_full_unstemmed | Human T-cell lymphotropic virus type 1 (HTLV-1) proposed vaccines: a systematic review of preclinical and clinical studies |
| title_short | Human T-cell lymphotropic virus type 1 (HTLV-1) proposed vaccines: a systematic review of preclinical and clinical studies |
| title_sort | human t cell lymphotropic virus type 1 htlv 1 proposed vaccines a systematic review of preclinical and clinical studies |
| topic | HTLV-1 Vaccine |
| url | https://doi.org/10.1186/s12879-023-08289-7 |
| work_keys_str_mv | AT niloofarseighali humantcelllymphotropicvirustype1htlv1proposedvaccinesasystematicreviewofpreclinicalandclinicalstudies AT armanshafiee humantcelllymphotropicvirustype1htlv1proposedvaccinesasystematicreviewofpreclinicalandclinicalstudies AT mohammadalirafiee humantcelllymphotropicvirustype1htlv1proposedvaccinesasystematicreviewofpreclinicalandclinicalstudies AT dlnyaaminzade humantcelllymphotropicvirustype1htlv1proposedvaccinesasystematicreviewofpreclinicalandclinicalstudies AT sayedhamidrezamozhgani humantcelllymphotropicvirustype1htlv1proposedvaccinesasystematicreviewofpreclinicalandclinicalstudies |